Granted Patent
B2
US 12,697,334 · App. 18/594,494 · Granted Aug 4, 2026
Methods and compositions for the treatment of hair loss
Assignee:
Aneira Pharma, Inc.
A61K31/506A61K9/0014A61K31/222A61K31/25A61K31/5575A61K31/58A61K38/13A61K47/10A61K47/12A61K47/26A61P17/14
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compositions and methods for the treatment of hair growth and the prevention of hair loss.
Claims (20)
1 . A topical solution for use in growing hair in a human patient wherein the active agents consist of about 0.02-0.2% w/v latanoprost and about 2-7% w/v minoxidil.
2 . The topical solution according to claim 1 wherein the patient applies about 1 ml of solution per day to the area of hair loss on the scalp.
3 . The topical solution of claim 2 wherein the patient is suffering from hair loss.
4 . The topical solution of claim 1 wherein the solution is comprised of about 40%-50% w/v propylene glycol.
5 . The topical solution of claim 4 wherein the solution is comprised of about 40% w/v propylene glycol.
6 . The topical solution of claim 4 wherein the solution is comprised of about 50% w/v propylene glycol.
7 . The topical solution of claim 2 wherein the patient experiences an increase in hair density in the area where the formulation is applied within 45 days of daily use.
8 . The topical solution of claim 1 wherein the solution is applied to the locale of hair follicles on the scalp where there is hair loss.
9 . The topical solution of claim 1 wherein the solution is applied to prevent hair loss.
10 . The topical solution of claim 1 wherein the solution is applied to the eyebrows.
11 . The topical solution of claim 1 wherein the patient applies about 0.1 ml per day to each eyebrow.
12 . The topical solution of claim 2 wherein the patient applies solution to the scalp by use of a dropper.
13 . The topical solution of claim 1 comprising 0.1% w/v latanoprost and 5% w/v minoxidil.
14 . The topical solution of claim 1 comprising 0.08% w/v latanoprost and 4% w/v minoxidil.
15 . The topical solution of claim 1 comprising 0.04% w/v latanoprost and 4% w/v minoxidil.
16 . The topical solution of claim 14 further comprising 40% propylene glycol.
17 . The topical solution of claim 14 further comprising 50% propylene glycol.
18 . The topical solution of claim 16 further comprising oleic acid.
19 . The topical solution of claim 17 further comprising ethanol.
20 . The topical solution of claim 17 further comprising oleyl alcohol.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 5, 2024
From: WURST, JOHN EDWARD
To: ANEIRA PHARMA, INC.
Reel/Frame 066650/0075 →
Continuity (7)
Provisional Application
63100611
· Mar 23, 2020
Provisional Application
62895869
· Sep 4, 2019
Provisional Application
62883809
· Aug 7, 2019
Related Publication
20240197734A1
· Jun 20, 2024
References Cited (128)
US 4139619A
· Chidsey, III
· 1979
[cited by applicant]
US 4596812A
· Chidsey, III et al.
· 1986
[cited by applicant]
US 4820512A
· Grollier
· 1989
[cited by applicant]
US 4828837A
· Uster et al.
· 1989
[cited by applicant]
US 5030442A
· Uster et al.
· 1991
[cited by applicant]
US 5225189A
· Pena
· 1993
[cited by applicant]
US 5407944A
· Goldman
· 1995
[cited by applicant]
US 5620980A
· Samour
· 1997
[cited by applicant]
US 5834014A
· Weiner et al.
· 1998
[cited by applicant]
US 6262105B1
· Johnstone
· 2001
[cited by applicant]
US 6403649B1
· Woodward et al.
· 2002
[cited by applicant]
US 6465514B1
· Hallam et al.
· 2002
[cited by applicant]
US 6596266B2
· Catalfo et al.
· 2003
[cited by applicant]
US 6946120B2
· So et al.
· 2005
[cited by applicant]
US 7388029B2
· Delong et al.
· 2008
[cited by applicant]
US 7442369B1
· Pena et al.
· 2008
[cited by applicant]
US 7749489B2
· Malek
· 2010
[cited by applicant]
US 7803357B2
· Cappello
· 2010
[cited by applicant]
US 8038988B2
· Woodward et al.
· 2011
[cited by applicant]
US 8293789B2
· Jimenez-Bayardo et al.
· 2012
[cited by applicant]
US 8454945B2
· Mccook et al.
· 2013
[cited by applicant]
US 8758733B2
· Ahluwalia et al.
· 2014
[cited by applicant]
US 8906962B2
· Delong et al.
· 2014
[cited by applicant]
US 9138480B2
· Trogden et al.
· 2015
[cited by applicant]
US 9149484B2
· Warner et al.
· 2015
[cited by applicant]
US 9226931B2
· Ahluwalia et al.
· 2016
[cited by applicant]
US 9700503B2
· Woodward et al.
· 2017
[cited by applicant]
US 9750750B2
· Trogden et al.
· 2017
[cited by applicant]
US 9763359B2
· Chan
· 2017
[cited by applicant]
US 9849140B2
· Warner et al.
· 2017
[cited by applicant]
US 20020077256A1
· Niemiec et al.
· 2002
[cited by applicant]
US 20040115234A1
· Gewirtz
· 2004
[cited by applicant]
US 20050079139A1
· Jacques et al.
· 2005
[cited by applicant]
US 20070160562A1
· Brinkenhoff
· 2007
[cited by applicant]
US 20080206156A1
· Cronk
· 2008
[cited by applicant]
US 20100204335A1
· Beddingfield et al.
· 2010
[cited by applicant]
US 20110136912A1
· Ketelson
· 2011
[cited by applicant]
US 20120129789A1
· Yoelin
· 2012
[cited by applicant]
US 20130041025A1
· Walt et al.
· 2013
[cited by applicant]
US 20140322148A1
· Jackson
· 2014
[cited by applicant]
US 20150072963A1
· Cotsarelis et al.
· 2015
[cited by applicant]
US 20160136071A1
· Corboy, Jr.
· 2016
[cited by applicant]
US 20160287704A1
· Herslöf
· 2016
[cited by applicant]
US 20180200263A1
· Grimes
· 2018
[cited by applicant]
CA 2309373A1
· 2000
[cited by applicant]
EP 3494955A1
· 2019
[cited by applicant]
JP 2001002535A
· 2001
[cited by applicant]
JP 2001511155A
· 2001
[cited by applicant]
JP 2003155218A
· 2003
[cited by applicant]
JP 2014510042A
· 2014
[cited by applicant]
JP 20165112246
· 2016
[cited by applicant]
WO 1998033497A1
· 1998
[cited by applicant]
WO 2005013928A1
· 2005
[cited by applicant]
WO 2007023841A1
· 2007
[cited by applicant]
WO 2009151828A1
· 2009
[cited by applicant]
WO 2011081861A2
· 2011
[cited by applicant]
WO 2012106249A2
· 2012
[cited by applicant]
WO 2013078259A2
· 2013
[cited by applicant]
WO 2013106565A1
· 2013
[cited by applicant]
WO 2013172838A1
· 2013
[cited by applicant]
WO 201415837
· 2014
[cited by applicant]
WO 2015176161A1
· 2015
[cited by applicant]
WO 2016124601A1
· 2016
[cited by applicant]
WO 2019034571A1
· 2019
[cited by applicant]
Baker SB, Dayan JH, Crane A, Kim S. The influence of brow shape on the perception of facial form and brow aesthetics. Plast Reconstr Surg. Jun. 2007;119(7):2240-2247. doi: 10.1097/01.prs.0000260771.76102.6c. PMID: 17519…
[cited by applicant]
Sadr J, Jarudi I, Sinha p. The role of eyebrows in face recognition. Perception. 2003;32(3):285-93. doi: 10.1068/p5027. PMID: 12729380.
[cited by applicant]
Van Der Velden EM, Drost BH, Ijsselmuiden OE, Baruchin AM, Hulsebosch HJ. Dermatography as a new treatment for alopecia areata of the eyebrows. Int J Dermatol. Aug. 1998;37(8):617-21. doi: 10.1046/j.1365-4362.1998.00540…
[cited by applicant]
Velez N, Khera P, English JC 3rd. Eyebrow loss: clinical review. Am J Clin Dermatol. 2007;8(6):337-46. doi: 10.2165/00128071-200708060-00003. PMID: 18039016.
[cited by applicant]
Jones D. Enhanced eyelashes: prescription and over-the-counter options. Aesthetic Plast Surg. Feb. 2011;35(1):116-21. doi: 10.1007/s00266-010-9561-3. Epub Aug. 21, 2010. PMID: 20730536; PMCID: PMC3036812.
[cited by applicant]
Vergilis-Kalner IJ. Application of bimatoprost ophthalmic solution 0.03% for the treatment of eyebrow hypotrichosis: series of ten cases. Dermatol Online J. Jun. 15, 2014;20(6):13030/qt1mc5v5mx. PMID: 24945645.
[cited by applicant]
Beer KR, Julius H, Dunn M, Wilson F. Treatment of eyebrow hypotrichosis using bimatoprost: a randomized, double-blind, vehicle-controlled pilot study. Dermatol Surg. Jul. 2013;39(7):1079-87. doi: 10.1111/dsu.12199. Epub…
[cited by applicant]
Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol. Feb. 2008;153(3):410-9. doi: 10.1038/sj.bjp.0707434. Epub Aug. 27, 2007. PMID: 17721551; PMCID: PMC22417…
[cited by applicant]
Tauchi M, Fuchs TA, Kellenberger AJ, Woodward DF, Paus R, Lütjen-Drecoll E. Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, an…
[cited by applicant]
Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Dermatol Surg. Sep. 2010;36(9):1361-71. doi: 10.1111/j.1524-4725.2010.01522.x. PMID: 20384750.
[cited by applicant]
Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. Apr. 26, 2010;4:349-58. doi: 10.2147/opth.s6480. PMID: 20463804; PMCID: PMC2861943.
[cited by applicant]
Fagien S. Management of hypotrichosis of the eyelashes: focus on bimatoprost. Plast Surg Nurs. Apr.-Jun. 2015;35(2):82-91. doi: 10.1097/PSN.0000000000000097. PMID: 26020474.
[cited by applicant]
Lee S, Tanglertsampan C, Tanchotikul M, Worapunpong N. Minoxidil 2% lotion for eyebrow enhancement: a randomized, double-blind, placebo-controlled, spilt-face comparative study. J Dermatol. Feb. 2014;41(2):149-52. doi: …
[cited by applicant]
Suwanchatchai W, Tanglertsampan C, Pengsalae N, Makornwattana M. Efficacy and safety of bimatoprost 0.03% versus minoxidil 3% in enhancement of eyebrows: a randomized, double-blind, split-face comparative study. J Derma…
[cited by applicant]
Deprost et al, Treatment of severe alopecia areata by topical applications of cyclosporin A: comparative trial versus placebo in 43 patients; Kluwer Academic Publishers, Trends in Human Growth and Alopecia Research, 198…
[cited by applicant]
Gihar et al., Topical cyclosporin in male pattrn alopecia, Journal of the American Academy of Dermotology, vol. 22, No. 2, Part 1, pp. 251-353, Feb. 1990.
[cited by applicant]
Inoue, Adverse Reaction after Use of Latanoprost in Japanese Glaucoma Patients, Ophthalmological Society, 2006, 110 vol., No. 8, pp. 581-587.
[cited by applicant]
Google English translation provided for Inoue, Adverse Reaction after Use of Latanoprost in Japanese Glaucoma Patients, Ophthalmological Society, 2006, 110 vol., No. 8, pp. 581-587.
[cited by applicant]
Woodward, Bimatoprost: A Novel Antiglaucoma Agent, Cardiovascular Drug Reviews, vol. 22, No. 2, pp. 103-120, 2004.
[cited by applicant]
Porter, Mouse models for human hair loss disorders, Journal Anatomical Society of Great Britain and Ireland 2003, 202, pp. 125-131, 2003.
[cited by applicant]
Aditya Gupta, et al., Efficacy of Off-Label Treatments for the Management of Androgenetic Alopecia: A Review, Clinical Drug Investigation, Jan. 2019, 8 pages.
[cited by applicant]
Ahmed Abdulhussein Kawen, Topical Minoxidil alone and with Lanoprost in Localized Alopecia Areata Treatment: Comparative Study (2019-2020), Systematic Review Pharmacy, vol. 11, Issue 4, pp. 164-169, 2020.
[cited by applicant]
Amal Ahmad El-Ashmawy, et al, Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment of alopecia areata, Journal of Dermatological Treatment, vol. 29, No. 1, Jun. 15, 2017, pp. 55-6…
[cited by applicant]
Bloch et al., Latanoprost and minoxidil: Comparative double-blind , placebo-controlled study for the treatment of hair loss, Surg Cosmet Dermatol. Rio de Janeiro v. 10 n.1 Jan.-Mar. 2018 p. 39-43, DOI: http://dx.doi.org…
[cited by applicant]
Clinical Investigation, A Prospective Study of Iridial Pigmentation and Eyelash Changes Due to Ophthalmic Treatment with Latanoprost, Japanese Journal of Ophthalmology, Mar. 2004, vol. 48, Issue 2, pp. 141-147 (first on…
[cited by applicant]
Coleman, H., The Cosmetic Effects of Bimatoprost vs. Latanoprost vs. Travoprost vs. Placebo on Eyelash Growth. American Academy of Optometry, 2010, 3 pages.
[cited by applicant]
Edited by Rowe et al., (2009), “Handbook of Pharmaceutical Excipients (6th ed.)”, London: APhA, (PhP) Pharmaceutical Press., pp. 468-470. (Year: 2009).
[cited by applicant]
Feidler-Weiss, Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata, Journal of American Academy of Dermatology, vol. 16, No. 3, part 2, pp. 745-748, Mar. 1987.
[cited by applicant]
Garg et al, Alpoecia areata: edivence-based treatments, Semin Cutan Med Sug., Mar. 2009, one page.
[cited by applicant]
Gita Faghihi, et al, The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows, Eur J Dermatol, 2009; 19, pp. 586-587.
[cited by applicant]
Hawkshaw et al., Identifying novel strategies for treating human hair loss disorders: Cyclosporine A suppresses the Wnt inhibitor, SFRP1, in the dermal papilla of human scalp hair follicles, PLOS Biology Fifteenth Anniv…
[cited by applicant]
Hideo Uno et al, Effect of Latanoprost on Hair Growth in the Bald Scalp of the Stump-tailed Macacque: A Pilot Study, Acta Derm Venereol, 2002, pp. 7-12.
[cited by applicant]
Im Coronel-Perez, et al, Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis, DJEADV, 2010, No. 24, pp. 481-485.
[cited by applicant]
Johnstone et al., Prostaglandin-Induced Hair Growth, Survey of Ophthalmology, vol. 47, supplement 1, Aug. 2002.
[cited by applicant]
Jorge Ocampo-Garza, et al, New drugs under investigation for the treatment of alopecias, Expert Opinion on Investigational Drugs, Issn 1354-3784, Jan. 15, 2019, 34 pages.
[cited by applicant]
Justine A. Ellis, et al., Male pattern baldness: current treatments, future prospects, Drug Discovery Today, vol. 13, No. 17/18, Sep. 2008, pp. 791-797.
[cited by applicant]
Karzan G. Khidir, et al, The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias, The FASEB Journal, 27 (2), Feb. 2013, pp. 557-567.
[cited by applicant]
Lauren L. Levy, et al, Female pattern alopecia: current perspectives, International Journal of Women's Health, Aug. 28, 2013, pp. 541-556.
[cited by applicant]
McCarey et al. “Low Incidence of Iris Pigmentation andEyelash Changes in 2 Randomized Clinical Trials with Unoprostone Isopropyl 0.15%” American Academy of Opthalmology, pp. 1480-1488, 2004.
[cited by applicant]
Murad, et al, Treatment for facial alopecia areata: A systematic review with evidence-based analysis, Journal of American Dermatology, Apr. 14, 2017, 10 pages.
[cited by applicant]
National Center for Biotechnology Information. “PubChem Compound Summary for CID 8146, Diethylene glycol monoethyl ether” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Diethylene-glycol-monoethyl-ether. Created Mar…
[cited by applicant]
Osborne, David; Skin Penetration and Permeation Properties of Transcutol®—Neat or Diluted Mixtures, AAPS PharmSciTech, vol. 19, No. 8, Nov. 2018, pp. 3513-3533.
[cited by applicant]
Ozyurt S., et al, Hypertrichosis of the malar areas and poliosis of the eyelashes caused by latanoprost, Actas Dermosifiliogr, 2015, pp. 74-75.
[cited by applicant]
Patel et al., Bioanalytical Method Development and Validation for Latanoprost Quantification in Pharmaceutical Opthalmic Microemulsion Formulation by RP-HPLC, Journal of Analytical & Bioanalytical Techniques, vol. 6, is…
[cited by applicant]
Paula M. Oliveira, et al, LC-MS bioanalytical method for simultaneous determination of latanoprost and minoxidil in the skin, Journal of Pharmaceutical and Biomedical Analysis, Mar. 6, 2020, 26 pages.
[cited by applicant]
Pfizer Manufacturing Belgium NV, Xalatan Package Insert for the 2.5 mL fill—Package of 1 Bottle, Aug. 2011, 14 pages.
[cited by applicant]
Rajarshi Mukhopadhyay, et al, A rare complication from prostaglandin analogue therapy, Clinical and Experimental Optometry, 2009, 92:2, pp. 137-138.
[cited by applicant]
S. Sasaki, et al, Influence of prostaglandin F2a and its analogues on hair regrowth and follicular melanogenesis in a murine model, Experimental Dermatology, 2005, pp. 323-328.
[cited by applicant]
Sardesai et al, A Study to Evaluate the Efficacy of Various Topical Treatment Modalities for Alopecia Areata, International Journal of Trichology, Oct.-Dec. 2012, 4 (4), pp. 265-270.
[cited by applicant]
Schweiger et al., Topical Bimatoprost for the Treatment of Eyebrow Hypotrichosis, Journal of Drugs in Dermatology, vol. II, Issue I, Jan. 2012, 106-108.
[cited by applicant]
T. Ogiso, et al. Transfollicular Drug Delivery: Penetration of Drugs Through Human Scalp Skin and Comparison of Penetration Between Scalp and Abdominal Skins In Vitro, Journal of Drug Targeting, 2002, vol. 10 (5), pp. 3…
[cited by applicant]
Ulrike Blume-Peytavi, et al., A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with…
[cited by applicant]
Williams, et al., “Penetration Enhancers”, 2004, Advanced Drug Delivery Reviews, 56(5), pp. 603-618. (doc.org/10.1016/j.addr.2003.10.025) (Year: 2004).
[cited by applicant]
Y. Liang et al, Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variat complexes, British Journal of Pharmacology, 2008, pp. 1079-1093.
[cited by applicant]